RM Global Partners

RM Global Partners

RM Global Partners was founded in 1992 as a life sciences investment bank and strategic advisory firm. The firm operates from headquarters in New York and an office in Tel Aviv, positioning itself at the intersection of US capital markets and Israeli health-tech innovation. Its advisory work spans biopharmaceuticals, medical devices, diagnostics and consumer digital health — a deliberate concentration that has shaped its entire deal flow and talent base for three decades. The firm’s core business is transaction advisory: mergers, acquisitions, licensing deals and private financings for companies from startup to multinational scale. It also runs a fund management arm anchored by the RMGP BioPharma Investment Fund, a vehicle built in collaboration with strategic partners that have included Johnson & Johnson and Takeda. The fund targets early-stage biotechnology opportunities, drawing on the firm’s transatlantic sourcing capability. The advisory and fund businesses reinforce each other — advisory mandates surface deal flow, and the fund provides a vehicle for the principals and their limited partners to commit capital alongside the strategic advice. RM Global Partners lists six managing directors — Bruce Roberts, Ted Moon, Yaron Breski, Assaf Keret, Lisa Wisniewski and Jack Springer — supported by a director and two associates. The firm clears securities transactions through Beech Hill Securities, a FINRA-member broker-dealer, which provides its regulatory infrastructure. The leadership group reflects the firm’s geographic split: US-based senior bankers run coverage in North America while the Tel Aviv office, led by Yaron Breski, anchors the firm’s Israeli deal sourcing and bio-innovation relationships. What distinguishes RM Global Partners structurally is its two-pronged model: an advisory practice that earns fees from transaction mandates, paired with a proprietary biopharma fund that allows the firm to invest principal and third-party capital into the same sector it advises. That alignment — or potential conflict — places it closer to a merchant banking construct than a pure advisory shop, a structure more common in European family offices than among US FINRA-member firms of its size.